Comparison

Anti-Mouse PD-L1 Antibody (Clone 10F.9G2) – Purified in vivo GOLD™ Functional Grade

Item no. LEIN-P363-1.0mg
Manufacturer Leinco Technologies
Amount 1 mg
Quantity options 1 mg 100 mg 25 mg 5 mg 50 mg
Category
Type Antibody Monoclonal
Applications WB, FC, IHC, other, IV
Clone 10F.9G2
Specific against Mouse (Murine, Mus musculus)
Host Rat
Purity > 95% by SDS-PAGE and ≥ 95% monomer by analytical SEC
Citations 1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668.
2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117.
3.) Gubin et al. (2018) Cell. 175:1014–1030
NCBI 60533
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Shipping condition Cool pack
Available
Manufacturer - Category
Purified in vivo Functional Grade>Gold Purified Bulk Antibodies|Primary Monoclonal Antibodies>Growth Factors and Cytokines|Primary Monoclonal Antibodies>Immune Checkpoints|Primary Monoclonal Antibodies>Surfacetag Mouse CD Markers
Manufacturer - Targets
PD-L1
Country of Origin
USA
Shipping Temperature
Next Day 2-8°C
Storage Conditions
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Product Description
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
PubMed
PD-L1
Ligand/Receptor
PD-1 (PDCD1)
Manufacturer - Research Area
Cancer, Costimulatory Molecules
Manufacturer - Specificity
Clone 10F.9G2 recognizes an epitope on mouse PD-L1.
RRID
AB_2749826
Concentration
≥ 5.0 mg/ml
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Endotoxin Level
≤ 1.0 EU/mg
Immunogen
UnKnown
Additonal Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mg
Available: In stock
available

Delivery expected until 1/31/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close